
Agenus Reports Landmark BOT+BAL Data at ESMO GI 2026
Agenus Reports Landmark Three-Year Phase 1b Data Showing Durable Survival with Botensilimab Plus Balstilimab in Refractory MSS Metastatic Colorectal Cancer Agenus Inc., a biotechnology company focused on advancing next-generation immuno-oncology therapies, has announced encouraging three-year follow-up data from its fully…













